Antibody therapy for acute myeloid leukaemia

Gemtuzumab ozogamicin in acute myeloid leukemia: a remarkable saga about an active drug

(2013) J. M. Rowe et al.   BLOOD

A phase 3 study of gemtuzumab ozogamicin during induction and postconsolidation therapy in younger patients with acute myeloid leukemia

(2013) S. H. Petersdorf et al.   BLOOD

SGN-CD33A: a novel CD33-targeting antibody-drug conjugate using a pyrrolobenzodiazepine dimer is active in models of drug-resistant AML

(2013) M. S. Kung Sutherland et al.   BLOOD

Targeting of acute myeloid leukaemia by cytokine-induced killer cells redirected with a novel CD123-specific chimeric antigen receptor

(2013) Sarah Tettamanti et al.   BRITISH JOURNAL OF HAEMATOLOGY

Redirection of T cells with a first fully humanized bispecific CD33–CD3 antibody efficiently eliminates AML blasts without harming hematopoietic stem cells

(2013) C Arndt et al.   LEUKEMIA

Genomic and Epigenomic Landscapes of Adult De Novo Acute Myeloid Leukemia

(2013)   NEW ENGLAND JOURNAL OF MEDICINE

Targeting the Intracellular WT1 Oncogene Product with a Therapeutic Human Antibody

(2013) T. Dao et al.   Science Translational Medicine

Addition of bevacizumab to chemotherapy in acute myeloid leukemia at older age: a randomized phase 2 trial of the Dutch-Belgian Cooperative Trial Group for Hemato-Oncology (HOVON) and the Swiss Group for Clinical Cancer Research (SAKK)

(2012) G. J. Ossenkoppele et al.   BLOOD

Engulfment of hematopoietic stem cells caused by down-regulation of CD47 is critical in the pathogenesis of hemophagocytic lymphohistiocytosis

(2012) T. Kuriyama et al.   BLOOD

A phase 1 trial of the anti-inhibitory KIR mAb IPH2101 for AML in complete remission

(2012) N. Vey et al.   BLOOD

All-trans-retinoic acid, idarubicin, and IV arsenic trioxide as initial therapy in acute promyelocytic leukemia (APML4)

(2012) H. J. Iland et al.   BLOOD

Acute myelogenous leukemia stem cells: From Bench to Bedside

(2012) J. Felipe Rico et al.   CANCER LETTERS

Recent advances in acute myeloid leukemia stem cell biology

(2012) S. J. Horton et al.   HAEMATOLOGICA

Targeted inhibition of VEGF-modulated survival and arsenic sensitivity in acute myeloid leukemia (AML)

(2012) Yong Ding et al.   Hematology

Phase I Trial of Anti-CD22 Recombinant Immunotoxin Moxetumomab Pasudotox (CAT-8015 or HA22) in Patients With Hairy Cell Leukemia

(2012) Robert J. Kreitman et al.   JOURNAL OF CLINICAL ONCOLOGY

Addition of Gemtuzumab Ozogamicin to Induction Chemotherapy Improves Survival in Older Patients With Acute Myeloid Leukemia

(2012) Alan K. Burnett et al.   JOURNAL OF CLINICAL ONCOLOGY

Effect of gemtuzumab ozogamicin on survival of adult patients with de-novo acute myeloid leukaemia (ALFA-0701): a randomised, open-label, phase 3 study

(2012) Sylvie Castaigne et al.   LANCET

Generation, selection and preclinical characterization of an Fc-optimized FLT3 antibody for the treatment of myeloid leukemia

(2012) M Hofmann et al.   LEUKEMIA

T lymphocytes can be effectively recruited for ex vivo and in vivo lysis of AML blasts by a novel CD33/CD3-bispecific BiTE antibody construct

(2012) M Aigner et al.   LEUKEMIA

FLT3 inhibition: a moving and evolving target in acute myeloid leukaemia

(2012) A Y H Leung et al.   LEUKEMIA

Targeting the FMS-like tyrosine kinase 3 in acute myeloid leukemia

(2012) R Swords et al.   LEUKEMIA

Anti-CD47 antibodies promote phagocytosis and inhibit the growth of human myeloma cells

(2012) D Kim et al.   LEUKEMIA

Clonal evolution in relapsed acute myeloid leukaemia revealed by whole-genome sequencing

(2012) Li Ding et al.   NATURE

Clonal Architecture of Secondary Acute Myeloid Leukemia

(2012) Matthew J. Walter et al.   NEW ENGLAND JOURNAL OF MEDICINE

Anti-CD20 Antibody Therapy for B-Cell Lymphomas

(2012) David G. Maloney   NEW ENGLAND JOURNAL OF MEDICINE

Enhanced ADCC Activity of Affinity Maturated and Fc-Engineered Mini-Antibodies Directed against the AML Stem Cell Antigen CD96

(2012) Sahar Mohseni Nodehi et al.   PLoS One

Inhibitory signaling through signal regulatory protein-  is not sufficient to explain the antitumor activities of CD47 antibodies

(2012) D. R. Soto-Pantoja et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

On the mechanism of CD47 targeting in cancer

(2012) X. W. Zhao et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Antibody therapy targeting the CD47 protein is effective in a model of aggressive metastatic leiomyosarcoma

(2012) B. Edris et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

The CD47-signal regulatory protein alpha (SIRPa) interaction is a therapeutic target for human solid tumors

(2012) S. B. Willingham et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Autologous transplantation gives encouraging results for young adults with favorable-risk acute myeloid leukemia, but is not improved with gemtuzumab ozogamicin

(2011) H. F. Fernandez et al.   BLOOD

Therapeutic Advances in Acute Myeloid Leukemia

(2011) Alan Burnett et al.   JOURNAL OF CLINICAL ONCOLOGY

Targeted Therapy With the T-Cell–Engaging Antibody Blinatumomab of Chemotherapy-Refractory Minimal Residual Disease in B-Lineage Acute Lymphoblastic Leukemia Patients Results in High Response Rate and Prolonged Leukemia-Free Survival

(2011) Max S. Topp et al.   JOURNAL OF CLINICAL ONCOLOGY

CD52 as a molecular target for immunotherapy to treat acute myeloid leukemia with high EVI1 expression

(2011) Y Saito et al.   LEUKEMIA

Prospective separation of normal and leukemic stem cells based on differential expression of TIM3, a human acute myeloid leukemia stem cell marker

(2011) M. Jan et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Gemtuzumab ozogamicin as postremission treatment in AML at 60 years of age or more: results of a multicenter phase 3 study

(2010) B. Lowenberg et al.   BLOOD

Leukemia-initiating cells from some acute myeloid leukemia patients with mutated nucleophosmin reside in the CD34- fraction

(2010) D. C. Taussig et al.   BLOOD

Novel conjugates of single-chain Fv antibody fragments specific for stem cell antigen CD123 mediate potent death of acute myeloid leukaemia cells

(2010) Christoph Stein et al.   BRITISH JOURNAL OF HAEMATOLOGY

A recombinant trispecific single-chain Fv derivative directed against CD123 and CD33 mediates effective elimination of acute myeloid leukaemia cells by dual targeting

(2010) Markus Kügler et al.   BRITISH JOURNAL OF HAEMATOLOGY

Therapeutic Antibody Targeting of CD47 Eliminates Human Acute Lymphoblastic Leukemia

(2010) Mark P. Chao et al.   CANCER RESEARCH

Anti-CD47 Antibody Synergizes with Rituximab to Promote Phagocytosis and Eradicate Non-Hodgkin Lymphoma

(2010) Mark P. Chao et al.   CELL

TIM-3 Is a Promising Target to Selectively Kill Acute Myeloid Leukemia Stem Cells

(2010) Yoshikane Kikushige et al.   Cell Stem Cell

Sequential Cytarabine and  -Particle Immunotherapy with Bismuth-213-Lintuzumab (HuM195) for Acute Myeloid Leukemia

(2010) T. L. Rosenblat et al.   CLINICAL CANCER RESEARCH

Human acute myelogenous leukemia stem cells are rare and heterogeneous when assayed in NOD/SCID/IL2Rγc-deficient mice

(2010) Jean-Emmanuel Sarry et al.   JOURNAL OF CLINICAL INVESTIGATION

Identification of Patients With Acute Myeloblastic Leukemia Who Benefit From the Addition of Gemtuzumab Ozogamicin: Results of the MRC AML15 Trial

(2010) Alan K. Burnett et al.   JOURNAL OF CLINICAL ONCOLOGY

Targeted delivery of SiRNA to CD33-positive tumor cells with liposomal carrier systems

(2010) Miriam Rothdiener et al.   JOURNAL OF CONTROLLED RELEASE

Effective Elimination of Acute Myeloid Leukemic Cells by Recombinant Bispecific Antibody Derivatives Directed Against CD33 and CD16

(2010) Heiko Singer et al.   JOURNAL OF IMMUNOTHERAPY

Anti-leukemic activity of Lintuzumab (SGN-33) in preclinical models of acute myeloid leukemia

(2010) May Kung Sutherland et al.   mAbs

Monoclonal antibody therapy directed against human acute myeloid leukemia stem cells

(2010) R Majeti   ONCOGENE

Induction of complete and molecular remissions in acute myeloid leukemia by Wilms' tumor 1 antigen-targeted dendritic cell vaccination

(2010) V. F. Van Tendeloo et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Identification of Therapeutic Targets for Quiescent, Chemotherapy-Resistant Human Leukemia Stem Cells

(2010) Y. Saito et al.   Science Translational Medicine

Allogeneic hematopoietic cell transplantation after conditioning with 131I-anti-CD45 antibody plus fludarabine and low-dose total body irradiation for elderly patients with advanced acute myeloid leukemia or high-risk myelodysplastic syndrome

(2009) J. M. Pagel et al.   BLOOD

Preclinical characterization of 1-7F9, a novel human anti-KIR receptor therapeutic antibody that augments natural killer-mediated killing of tumor cells

(2009) F. Romagne et al.   BLOOD

Bispecific T-Cell Engaging Antibodies for Cancer Therapy

(2009) P. A. Baeuerle et al.   CANCER RESEARCH

CD47 Is an Adverse Prognostic Factor and Therapeutic Antibody Target on Human Acute Myeloid Leukemia Stem Cells

(2009) Ravindra Majeti et al.   CELL

Monoclonal Antibody-Mediated Targeting of CD123, IL-3 Receptor α Chain, Eliminates Human Acute Myeloid Leukemic Stem Cells

(2009) Liqing Jin et al.   Cell Stem Cell

The Prioritization of Cancer Antigens: A National Cancer Institute Pilot Project for the Acceleration of Translational Research

(2009) M. A. Cheever et al.   CLINICAL CANCER RESEARCH

Targeting C-type lectin-like molecule-1 for antibody-mediated immunotherapy in acute myeloid leukemia

(2009) X. Zhao et al.   HAEMATOLOGICA

A novel AML-selective TRAIL fusion protein that is superior to Gemtuzumab Ozogamicin in terms of in vitro selectivity, activity and stability

(2009) B ten Cate et al.   LEUKEMIA

Monoclonal antibodies against IREM-1: potential for targeted therapy of AML

(2009) W Korver et al.   LEUKEMIA

The CD300 family of molecules are evolutionarily significant regulators of leukocyte functions

(2009) Georgina J. Clark et al.   TRENDS IN IMMUNOLOGY

Age and acute myeloid leukemia: real world data on decision to treat and outcomes from the Swedish Acute Leukemia Registry

(2008) G. Juliusson et al.   BLOOD

Effective Treatment of Acute Promyelocytic Leukemia With All-Trans-Retinoic Acid, Arsenic Trioxide, and Gemtuzumab Ozogamicin

(2008) Farhad Ravandi et al.   JOURNAL OF CLINICAL ONCOLOGY

Phase I clinical study of diphtheria toxin-interleukin 3 fusion protein in patients with acute myeloid leukemia and myelodysplasia

(2008) Arthur Frankel et al.   LEUKEMIA & LYMPHOMA